Loading…
Generic-drug maker also developing specialty drugs for Parkinson's disease and other conditions.
Generic-drug maker also developing specialty drugs for Parkinson's disease and other conditions.
Sells most products to three big drug wholesalers that supply US pharmacies, so a few buyers set terms on generics, where price competition is intense. To offset that, it has been adding branded specialty drugs, such as Crexont, approved in 2024, and biosimilars, copies of biologic medicines, from partners.
Moat: narrow (scale, cost advantage). Vertically integrated US generics manufacturing scale, with a smaller specialty franchise for differentiation.
Headquarters: Bridgewater, New Jersey, United States · Founded: 2002 · Employees: 8,500
Size Amneal Pharmaceuticals (AMRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.01B, the 959th largest of 3,117 United States companies the cockpit tracks. Shares closed at $20.14 on 6 Nov 2026.
Performance Over six months the shares gained 52.6%, against +1.1% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 8.9% over the last twelve months (peer median +5.7%); the operating margin is 16.5% (peer median 13.7%).
Valuation It trades at 17.7× forward earnings against a peer median of 24.0× (7th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.5 points above its cost of capital (9.3% WACC).
Short interest Short interest is 4.4% of the free float (15 Oct 2026).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $3.20B | $3.02B | $2.79B | $2.39B | $2.21B |
| Revenue growth | — | +8% | +17% | +8% | — |
| Gross profit | $1.29B | $1.14B | $1.02B | $857M | $796M |
| EBITDA | $722M | $647M | $589M | $492M | $441M |
| Net income | $133M | $72.1M | -$117M | -$84.0M | -$130M |
| Free cash flow | $38.4M | $241M | $235M | $136M | $14.6M |
| Capital expenditure | $242M | $114M | $75.0M | $69.2M | $90.6M |
| Total debt | $3.28B | $2.69B | $2.59B | $2.75B | $2.85B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals AMRX | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.7B | +19% | -4% | 19% | 15.1× | 10.2% |
| Viatris VTRS | $22.9B | +17% | +5% | 10% | 7.5× | 12.5% |
| Amphastar Pharmaceuticals AMPH | $1.21B | +50% | +1% | 16% | 8.9× | 3.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.5% | +2.6% | 11th highest of 21 |
| 6-month return | +52.6% | +1.1% | 3rd highest of 21 |
| Distance from 52-week high | -7.1% | -16.4% | 4th highest of 21 |
| Revenue growth (TTM) | +8.9% | +5.7% | 9th highest of 18 |
| Operating margin | 16.5% | 13.7% | 7th highest of 18 |
| Forward P/E | 17.7× | 24.0× | 7th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 15.2% | 8.4% | 5th most demanding of 11 |
| Growth delivered (Del g) | +8.7% | +10.7% | 4th lowest of 11 |
| Hurdle (Req g minus delivered) | +6.5 pp | -4.1 pp | 5th most demanding of 11 |
| ROIC minus cost of capital | +1.5 pp | +1.3 pp | 10th highest of 20 |
| EV / EBITDA | 14.2× | 21.1× | 3rd cheapest of 10 |
| Net debt / EBITDA | 4.3× | 0.3× | 4th most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 14.7× | -8.2% | +10.8% |
| RemeGen 9995.HK | Hong Kong | $6.92B | -31% | +293% | 61% | 7.4× | -4.8% | +57.9% |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 27.4× | 24.3% | +10.7% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | n/a | n/a | n/a |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% | +7.1% |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | n/a | n/a | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% | +18.4% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $6.40B | +21% | +14% | 20% | 29.7× | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.39B | -36% | n/a | -25% | 24.0× | n/a | n/a |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | n/a | 31.5% | +7.3% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 32.0× | 20.0% | +9.4% |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | n/a | n/a | n/a |
| Biocon BIOCON.NS | India | $6.28B | -4% | +6% | 8% | 56.4× | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.20B | 0% | n/a | n/a | n/a | n/a | n/a |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 16.4× | 24.9% | +16.6% |